Journal of Medicinal Chemistry · 2016 · 59 citations · 16 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryMolecular PharmacologyEnzyme InhibitionLigand BindingPotency OptimizationStructure-activity Relationship AnalysisHistone Demethylase InhibitionHistone DemethylasesHistone DemethylationMedicinal Chemistry ApplicationsSelectivitySmall Molecule Drug DesignSmall-molecule Library DesignTranscription Inhibitors
Optimization of KDM6B (JMJD3) HTS hit 12 led to the identification of 3-((furan-2-ylmethyl)amino)pyridine-4-carboxylic acid 34 and 3-(((3-methylthiophen-2-yl)methyl)amino)pyridine-4-carboxylic acid 39 that are inhibitors of the KDM4 (JMJD2) family of histone lysine demethylases. Compounds 34 and 39 possess activity, IC50 ≤ 100 nM, in KDM4 family biochemical (RFMS) assays with ≥ 50-fold selectivity against KDM6B and activity in a mechanistic KDM4C cell imaging assay (IC50 = 6-8 μM). Compounds 34 and 39 are also potent inhibitors of KDM5C (JARID1C) (RFMS IC50 = 100-125 nM).
16
A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response
Laurens Kruidenier, Chun‐wa Chung, Zhongjun Cheng et al. · Nature · 2012 · 958 citations · Full text
The putative oncogene GASC1 demethylates tri- and dimethylated lysine 9 on histone H3
Paul A. Cloos, Karl Agger, Alessio Maiolica et al. · Nature · 2006 · 749 citations
Shohei Hamada, Takayoshi Suzuki, Koshiki Mino et al. · Journal of Medicinal Chemistry · 2010 · 162 citations · Full text